All News #Library
Biotech
C4 Therapeutics Initiates Phase 1B Trial For Cemsidomide
25 Mar 2026 //
GLOBENEWSWIRE
C4 Therapeutics Doses First Patient in Phase 2 MOMENTUM Trial
23 Feb 2026 //
GLOBENEWSWIRE
C4 Therapeutics To Participate In Upcoming March Conferences
23 Feb 2026 //
GLOBENEWSWIRE
C4 Therapeutics Inducement Grant Under Nasdaq Lr 5635(C)(4)
09 Feb 2026 //
GLOBENEWSWIRE
C4 Therapeutics Joins Guggenheim Biotech Summit 2026
04 Feb 2026 //
GLOBENEWSWIRE
C4 Therapeutics Awards Inducement Grant Under Nasdaq Rule
26 Jan 2026 //
GLOBENEWSWIRE
C4 Therapeutics Advances Cemsidomide As Top IKZF1/3 Degrader
14 Jan 2026 //
GLOBENEWSWIRE
C4 Therapeutics To Join 8Th Evercore Healthcare Conference
25 Nov 2025 //
GLOBENEWSWIRE
C4 Therapeutics highlight Biogen Collaboration Success
04 Sep 2025 //
GLOBENEWSWIRE
C4 Therapeutics Delivers Second Development Candidate To Biogen
10 Sep 2024 //
GLOBENEWSWIRE
Merck & Co. inks deal with C4 on degrader-antibody conjugates
13 Dec 2023 //
GLOBENEWSWIRE

Market Place
Sourcing Support